A parallel study also tested the effects of the second-line PBC therapy, OCA, an FXR agonist and the most potent anti–cholestatic agent approved for use in PBC to date, on cognitive function in BDL mice.31 Here, NR1H4 is linked to primary biliary cholangitis.